Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
PR97350
MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire=KYODO JBN/ --
-Vittorio Sebastiano, globally recognized for pioneering science, expands his
role at company he co-founded as it moves closer to clinical research
Turn Biotechnologies, a cell rejuvenation company developing novel mRNA
medicines to cure untreatable, age-related conditions, today announced that
co-founder Vittorio Sebastiano, PhD, will become its head of research.
Photo - https://mma.prnewswire.com/media/1872938/Vittorio_Sebastiano_PhD.jpg
Sebastiano led development of the unique mRNA-based ERA(TM) (Epigenetic
Reprogramming of Aging) platform Turn Bio uses to produce tailored protein
cocktails to rejuvenate targeted cells. He assumes his role as head of research
this month. Sebastiano has served as chairman of Turn Bio's Scientific Advisory
Board since he co-founded the company in 2018.
A Stanford School of Medicine faculty member, author of more than 50 scientific
articles and frequent speaker at research conferences around the world,
Sebastiano is prominent in the emerging field of cellular reprogramming. His
Stanford University lab pioneered the development of a new paradigm for
treating aging and age-related diseases. He also led the team that first
confirmed human cells can be reprogrammed using Turn Bio's ERA platform.
"Vittorio's vision and leadership will propel Turn Bio's innovation and speed
our efforts to develop new therapies," said Anja Krammer, the company's CEO.
"He keenly understands the potential our science has to redefine the way
doctors treat age-related conditions, and shares our commitment to delivering a
steady stream of new solutions to the clinic."
Sebastiano, who has conducted research at prominent universities in Europe and
the United States, looks forward to bringing his academic research to life by
guiding the development of Turn Bio's therapies
"The next months will be incredibly exciting, as we bridge the gap between
academic science and the life-changing therapies so desperately needed by
millions of people around the world," said Sebastiano. "We have the potential
to cure diseases that are currently untreatable, improve the quality of life
for millions and truly transform and democratize medical care."
Sebastiano received his bachelor's and doctoral degrees from Università di
Pavia in Italy and completed post-doctoral work at the Max Planck Institute for
Molecular Biomedicine in Germany and Stanford. Since 2014, he has been an
associate professor of OBGyN at Stanford in the Stanford Institute for Stem
Cell Biology. He is the Woods Family Scholar in Pediatric Medicine, has served
as co-director of the Stanford Stem Cell PhD Program and has received
prestigious awards for his pioneering and revolutionizing approach to induce
cellular rejuvenation, including the 2017 American Federation for Aging
Research (AFAR) Junior Investigator Award and the 2019 Breakthrough in
Gerontology Award by AFAR and the Glenn Foundation.
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the
cellular level. The company's proprietary mRNA platform technology, ERA(TM),
restores optimal gene expression by combatting the effects of aging in the
epigenome. This restores the cells' ability to prevent or treat disease, heal
or regenerate tissue and fight incurable chronic diseases.
The company is currently completing pre-clinical research on tailored therapies
targeting indications in dermatology and immunology, as well as developing
therapies for ophthalmology, osteo-arthritis and the muscular system. For more
information, see www.turn.bio .
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
jim@rightstorygroup.com or (312) 543-9026
SOURCE Turn Biotechnologies
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。